Hematopoietic cancers, including leukemia, lymphoma, and multiple myeloma, constitute a heterogeneous group of malignancies characterized by intricate genetic and microenvironmental changes. In recent decades, therapeutic approaches have progressed from traditional chemotherapy and radiotherapy to advanced targeted and immune-based treatments. Hematopoietic stem cell transplantation (HSCT) continues to be a fundamental component of curative therapy enhanced by reduced-intensity regimens and innovative donor sources with increased accessibility. Concurrent advancements in small-molecule inhibitors, such as kinase and proteasome pathway modulators, have enhanced therapeutic precision by selectively targeting oncogenic signaling while minimizing toxicity. The development of monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and immune checkpoint inhibitors has further expanded therapeutic options by leveraging immune effector mechanisms. Cellular immunotherapies, notably CAR-T cells, have revolutionized outcomes in relapsed and refractory hematologic malignancies, whereas next-generation CAR constructs, CAR-NK cells, and tumor vaccines continue to broaden the scope of immune engineering. Simultaneously, nanotechnology has redefined drug delivery paradigms by improving pharmacokinetics, reducing systemic toxicity, and enabling tumor-targeted release of chemotherapeutics, molecular inhibitors, and immunomodulators. Smart nanocarriers, biomimetic systems, and nanodrug delivery platforms integrated with immunotherapies exemplify the shift towards precision and personalized medicine. Collectively, these advancements highlight a paradigm shift in hematopoietic cancer therapy, where the integration of molecular insights, immunological innovation, and nanotechnology is paving the way for durable remission, improved survival, and enhanced quality of life.